Merit Medical acquires Brightwater Medical

Huge Two-Day Clean Sweep Auction July 24-25th. Click Here to Bid!

advertisement
Ubicación actual:
>
>
> This Story

Forward Printable StoryPrint Comment
advertisement

 

advertisement

 

Cardiology Homepage

AHRA and Canon Medical Systems support medical imaging innovation with the 12th annual putting patients first program

European Society of Cardiology hosting digital summit in Tallinn

Abbott receives U.S. approval of next-generation MitraClip, bringing new enhancements to Abbott's leading MitraClip platform

Telehealth Technology to reduce hospital readmissions and improve outcomes for cardiac disease patients

FDA approves Bayer's Gadavist (gadobutrol) injection as first contrast agent for use in cardiac MR in adult CAD patients

New technology improves atrial fibrillation detection after stroke

New study of ultrasound enhancing agents in echocardiography reaffirms safety profile of LUMASON

Johns Hopkins Medicine researchers identify health conditions likely to be misdiagnosed

Team approach to cardiac care increases chance of surviving heart attack complications

Philips supports CNIC to shape the future of cardiac care

Merit Medical acquires Brightwater Medical

Press releases may be edited for formatting or style
SOUTH JORDAN, Utah, June 17, 2019 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a leading manufacturer and marketer of proprietary disposable devices used in interventional, diagnostic and therapeutic procedures, particularly in cardiology, radiology, oncology, critical care and endoscopy, announced today that it has acquired Brightwater Medical, Inc., based in Temecula, California. The transaction consists of a $35 million upfront payment and potential earn-out payments of up to $15 million based on receipt of CE mark approval and achievement of future sales targets.

Brightwater Medical was founded by Dr. Robert Smouse, Professor of Radiology and Surgery, University of Illinois College of Medicine. Its primary product, the ConvertX®, is a single device used to replace a series of devices and procedures used to treat severe obstructions of the ureter. The system is designed to be implanted once and converted from a nephroureteral catheter to a nephroureteral stent without requiring sedation or local anesthesia. Brightwater Medical recently received FDA clearance for the ConvertX® biliary stent system.

Story Continues Below Advertisement

Servicing GE Nuclear Medicine equipment with OEM trained engineers

We offer full service contracts, PM contracts, rapid response, time and material,camera relocation. Nuclear medicine equipment service provider since 1975. Click or call now for more information 800 96 NUMED



“The ConvertX® system is designed to reduce multiple visits to the hospital, saving patients the risk and discomfort of a second interventional procedure while allowing additional utilization of facilities,” said Fred P. Lampropoulos, Chairman and CEO of Merit Medical. “The ConvertX® system complements Merit’s Resolve™ drainage catheter portfolio and potentially drives pull-through of other Merit products such as InQwire™ guide wires, Advocate™ PTA balloons and other vascular products.”

Over the next several months, Merit Medical intends to maintain Brightwater Medical’s production capabilities in Temecula while duplicating those capabilities in its catheter facility in Pearland, Texas, prior to transferring the ConvertX® manufacturing operations to its Pearland facility. Merit Medical’s management estimates that the transaction will be approximately $(0.05) decretive to earnings per share for the year ending December 31, 2019 on a GAAP basis and approximately $(0.03) decretive to earnings per share for the year ending December 31, 2019 on a non-GAAP basis due to deal-related expenses, severance, transfer and integration costs, and international regulatory expenses. Management’s current revenue expectations for the ConvertX® product for calendar year 2019 are approximately $1 million with expectations of growth to approximately $25 million in the fifth full year of sales. Upon transfer of the ConvertX® manufacturing operations to Merit’s Pearland facility, management believes non-GAAP gross margins in the 70-75% range are attainable.
  Pages: 1 - 2 >>

Cardiology Homepage


You Must Be Logged In To Post A Comment